Analyst Upgrades

• State Street (STT) was upgraded to buy from neutral at Goldman.
• Roth Capital upgraded Intel (INTC), Marvell Technology (MRVL) and Nvidia (NVDA) to buy from neutral.
• Bebe Stores (BEBE) was upgraded to buy from neutral at Janney Montgomery.
• W&T Offshore (WTI) was upgraded to buy from accumulate at Global Hunter.
• Citigroup upgraded International Rectifier (IRF) and Timberland (TBL) to hold from sell.
• Watson Pharma (WPI) was upgraded to buy from neutral at UBS.
• Atmel (ATML) was upgraded to strong buy from buy at Needham.
• Ashford Hospitality (AHT) was upgraded to outperform from neutral at RW Baird.
• Oppenheimer upgraded MetroPCS (PCS) to outperform from perform.

It will be a busy week. Republicans are poised to gain control of the House of Representatives and gain governorships in Tuesday's mid-term elections. Also, the Federal Reserve is expected to announce another round of quantitative easing Wednesday, following the FOMC meeting. Major retailers are scheduled to report October same-store sales Thursday, while the October unemployment rate, announced on Friday, is expected to remain at 9.6%.

Toyota's (TM) fiscal second-quarter results will be one of the highlights on the earnings front this week. After three periods of way underestimating Toyota's earnings, have the analysts surveyed by Thomson Reuters got it right this time? The stock sure could use a boost. Teva Pharmaceuticals (TEVA) is in a similar situation; i.e., high expectations for this week's quarterly results but a stock in need of a boost. Marathon (MRO) and Starbucks (SBUX) are also expected to post strong earnings growth this week, but both stocks are riding high.

Analyst Upgrades

• Merriman upgraded Penn National (PENN) to buy from neutral, citing the company's strong balance sheet and management team. The firm also raised its target range for shares to $34 to $37.60.
• BMO Capital upgraded Cooper Companies (COO) to outperform from market perform and raised its price target to $55 from $46. The firm sees upside to Street estimates and increased visibility.
• Argus upgraded Watson Pharma (WPI) to buy from hold based on valuation.
• Phillips-Van Heusen (PVH) was upgraded to conviction buy from neutral at Goldman.
• Allstate (ALL) was upgraded to overweight from neutral at JPMorgan.
• Weingarten Realty (WRI) was upgraded to neutral from underperform at BofA/Merrill.

Analyst Upgrades

• Needham upgraded Dick's Sporting Goods (DKS) to buy from hold following the company's Q1 results as it believes the sell-off in shares provides an attractive entry point into the name. The firm has a $31 price target for the stock. Piper Jaffrey upgraded Dick's Sporting to overweight from neutral following the company's Q1 results and raised its target for shares to $34 from $31.
• Piper Jaffray also upgraded MGIC Investment (MTG) to overweight from neutral. The firm upgraded shares on valuation and raised its target to $11 from $10.
• Macy's (M) was upgraded to buy from neutral and VeriSign (VRSN) was upgraded to sell from conviction sell at Goldman.
• Fidelity National (FIS) was upgraded to outperform from market perform at Raymond James.
• Watson Pharma (WPI) was upgraded to overweight from neutral at JPMorgan.

Analyst Upgrades

• FBR Capital upgraded Wells Fargo (WFC) to market perform from underperform and raised its target on shares to $26 from $21 following the company's better-than-expected quarter.
• Deutsche Bank upgraded Starbucks (SBUX) to buy from hold following the company's better-than-expected Q1 results. The firm raised its target price on shares to $30 from $19.
• UBS upgraded Dreamworks (DWA) to buy from neutral, citing upside from its upcoming film releases. The firm raised its target to $50 from $35.
• Colgate (CL) was upgraded to conviction buy from buy at Goldman.
• F5 Networks (FFIV) was upgraded to buy from neutral at BofA/Merrill.
• Applied Industrial (AIT) was upgraded to overweight from equal weight at Stephens.

Analyst Upgrades

• Barclays upgraded Schlumberger (SLB) to overweight from equal weight based on its deep management team, financial strength and increased exploration activity. The firm raised its target to $73 from $64.
• ThinkEquity upgraded SanDisk (SNDK) to buy from hold based on expectations for a solid 2010 with better NAND pricing trends, leaner channel inventories and lack of new fabs slated in 2010, among other reasons. The firm has a $35 target on the stock.
• Keefe Bruyette upgraded Pinnacle Financial (PNFP) to outperform from market perform, citing the company's strong management and balance sheet. The firm has a $16.50 price target on the stock.
• Watson Pharma (WPI) was raised to neutral from underperform at BofA/Merrill.
• New York Times (NYT) was upgraded to market perform from underperform at Wells Fargo.
• Tenet Healthcare (THC) was upgraded to outperform from market perform at Leerink.

Analyst upgrades:

• Banc of America/Merrill upgraded DPL Inc (NYSE: DPL) to Neutral from Underperform following the settlement agreement with staff of the Public Utilities Commission of Ohio on Electric Security Plan.
  
• Friedman Billings upgraded SeaBright Insurance (NYSE: SBX) to Outperform from Market Perform on valuation as they believe shares are oversold at current levels. Despite upgrading, the firm lowered its target price to $14 from $16.
  
• JP Morgan upgraded AT&T (T) to Overweight from Neutral as it believes upside earnings revisions are likely in 2009 due to the company's conservative wireline margin outlook. The firm finds the stock's valuation attractive at current levels and raised their target on shares to $28 from $24.
• Chubb (NYSE: CB) was upgraded to buy from Neutral at UBS.
  
• Cascal B.V. (NYSE: HOO) was raised to Outperform from Neutral at Credit Suisse.
  
• Healthcare Realty Trust (NYSE: HR) was upgraded at Keefe Bruyette to Outperform from Market Perform.

Analyst upgrades:

• Baird upgraded Starwood Hotels (NYSE: HOT), Host Hotels (NYSE: HST) and Marriott (NYSE: MAR) to Outperform from Neutral based on valuation and indications that negative sentiment has reached a bottom.
• Citigroup upgraded Torchmark (NYSE: TMK) to Buy from Hold as they find the valuation attractive and think management can grow earnings and book value in 2009/2010. Despite upgrading, the firm lowered their target price to $37 from $45.
• ASM International (NASDAQ: ASMI) was added to Goldman's Conviction Buy List.
• Credit Suisse (NYSE: CS) was raised to Overweight from Equal Weight at Morgan Stanley.
• Live Nation (NYSE: LYV) was upgraded at Natixis to Buy from Hold.

It's one of those unfortunate facts of life, everyone is going to get sick at some time in their lives. It could be something as simple as the common cold or a complex series of symptoms that takes years to diagnose. The upside of all of this is that the medical business is a relatively safe bet when it comes to investments. If you see the benefit of this and want to put some money into a health care related investment, look into an Exchange Traded Fund (ETF) that will give you the opportunity to hold shares in several different companies rather than trying to guess who's going to come up with the next miracle cure.

There are a couple different companies that let you get your feet wet in the medical field. You could invest in medical devices, which covers everything from stethoscopes to complicated surgical tools. iShares Dow Jones US Medical Devices ETF (NYSE: IHI) lets you in on an investment that includes leaders in the field such as Boston Scientific Corporation (NYSE: BSX), Medtronic, Inc. (NYSE: MDT), and Covidien, Ltd. (NYSE: COV). Each of these companies provides medical devices that hospitals simply cannot do without.

IHI looks to achieve results that correspond to the Dow Jones US Select Medical Equipment index and through a computer aided system, rather than by using money managers, they're able to charge only a 0.48% fee to maintain your stock.

Another great way to invest in the healthcare business is to buy shares in the companies who work tirelessly to provide lifesaving drugs. The Exchange Traded Fund SPDR S&P Pharmaceuticals (XPH) lets you in on several of the top pharmaceutical companies in the world by following a passive management strategy that tracks the total return performance of the S&P Pharmaceutical Select Industry index.

Analyst upgrades:

• Keefe Bruyette upgraded shares of AllianceBernstein (NYSE: AB) to Outperform from Market Perform as they find AB's risk/reward attractive given its attractive long-term business model. Wachovia upgraded Watson Pharma (NYSE: WPI) and Teva Pharma (NASDAQ: TEVA) to Outperform from Market Perform citing valuations and positive drivers for generics that include patent expirations and market share expansion.
• UBS raised Lloyds TSB Group (NYSE: LYG) to Neutral from Sell on expected pricing power following the HBOS (OTC: HBOOY) acquisition.
• Otter Tail (NASDAQ: OTTR) was upgraded to Outperform from Neutral at Baird.
• GFI Group (NASDAQ: GFIG) was upgraded at Citigroup to Hold from Sell.
• Merrill upgraded Logitech (NASDAQ: LOGI) to Neutral from Underperform.

Analyst downgrades:

• JP Morgan downgraded shares of Lloyds TSB Group to Underweight from Neutral on capital concerns and believes the HBOS acquisition is not in the best interest of shareholders.
• Stephens downgraded Universal Truckload (NASDAQ: UACL) to Equal Weight from Overweight on valuation and concerns about a slowdown in the flatbed sector. The firm's target remains $28.

MOST NOTEWORTHY: Stanley Works, the Generic Drug sector, Fiserv and Fidelity National were today's noteworthy downgrades:

• Deutsche Bank downgraded shares of Stanley Works (NYSE: SWK) to Hold from Buy as they see risk to Q2 and FY08 earnings due to a slowdown in the European industrial and consumer categories. The firm lowered their target to $52 from $62.
  
• Wachovia cut the Generic Drug sector to Market Weight from Overweight Wachovia sees near-term challenges for Teva Pharmaceutical (NASDAQ: TEVA), Mylan (NYSE: MYL) and Watson Pharmaceuticals (NYSE: WPI). The firm thinks Teva will become a very strong company over the long-term, following its takeover of Barr (NYSE: BRL). However, the firm adds that Teva will need to integrate the acquisition nearly perfectly, and Mylan may feel compelled to make another acquisition, even as it is still integrating Merck Generics, while Watson's growth prospects are still uncertain.
  
• Oppenheimer downgraded Fiserv (NASDAQ: FISV) and Fidelity National (NYSE: FIS) to Perform from Outperform based on multiple pressure from the challenging banking environment and growth headwinds.

OTHER DOWNGRADES:

• Satyam (NYSE: SAY) was downgraded to Underperform from Outperform at Credit Suisse and Equal Weight from Overweight at Morgan Stanley.
  
• UBS downgraded Textron (NYSE: TXT) to Neutral from Buy.
  
• Constellation Energy (NYSE: CEG) was downgraded at Jefferies to Underperform from Hold.

MOST NOTEWORTHY: NICE Systems, Watson Pharmaceuticals and Micron Tech were today's noteworthy upgrades:

• NICE Systems (NASDAQ: NICE) was upgraded to Buy from Neutral at UBS, as they believe NICE is well-positioned to leverage its offerings in VoIP recording, call centre analytics, and other applications with its extensive enterprise customer base.
  
• Hambrecht upgraded shares of Watson Pharmaceuticals (NYSE: WPI) to Buy from Hold ahead of the company's Q4 results to reflect valuation and low expectations.
  
• Thomas Weisel upgraded Micron Tech (NYSE: MU) to Overweight from Market Weight citing expectations DRAM pricing will stabilize in 2008, potential upside from high growth DRAM segments such as mobile, and notes cost cutting efforts and valuation.

OTHER UPGRADES:

• JP Morgan added Wabtec (NYSE: WAB) to its Focus List.
  
• Keefe Bruyette raised Franklin Bank (NASDAQ: FBTX) to Market Perform from Underperform.
  
• Morgan Stanley upgraded Wyeth (NYSE: WYE) to Overweight from Equal Weight.
  
• Citigroup upgraded Mentor Graphics (NASDAQ: MENT) to Buy from Hold and added shares to its Top Picks List.

Monday, November 12

• Veterans' Day holiday.
• Tyson Foods (NYSE: TSN) to report Q4 earnings. They are holding a conference call at 9am and a business update later at 10:45am.

Tuesday, November 13

• Wal-Mart Stores (NYSE: WMT) to report Q3 earnings; pre-recorded conference call at 7am.
• Home Depot (NYSE: HD) to report Q3 earnings; conference call at 9am.
• Fed Reserve Governor Randall Kroszner is the Keynote Speaker at Standard & Poor's Banking Conference in New York at 1pm.

Wednesday, November 14

• Fed Reserve Chairman Ben Bernanke is the Keynote Speaker at Cato Institute Annual Monetary Conference at 9:10am.
• Macy's (NYSE: M) to report Q3 earnings; conference call at 10:30am.

Thursday, November 15

• Charles Schwab (NASDAQ: SCHW) to hold business update conference call at 10:30am.
• Nevada District Court: Bayer (NYSE: BAY) vs. Watson Pharmaceuticals (NYSE: WPI) on Patent Infringement Lawsuit over the generic birth control drug YAZ.

Friday, November 16

• PDUFA date for Bristol Myers Squibb Company's (NYSE: BMY) Abilify.
  
• PDUFA date for Impax Laboratories' (OTC: IPXL) Vadova.

MOST NOTEWORTHY: BT Group, Luminent Mortage, Cognos, Thor Industries and Watson Pharmaceuticals were today's noteworthy upgrades:

• ING Group upgraded shares of BT Group (NYSE: BT) to Hold from Sell to reflect the company's more stable revenue trend and improving cash flow generation.
  
• Deutsche Bank upgraded shares of Luminent Mortgage Capital (NYSE: LUM) to Hold from Sell, as they believe the company's portfolio is beginning to stabilize and its liquidity has improved.
  
• Goldman upgraded Cognos Inc (NASDAQ: COGN) to Buy from Neutral following its Q2 report.
  
• Thor Industries (NYSE: THO) was raised to Sector Perform from Underperform at RBC Capital Markets. The firm's checks indicate strengthening backlog and lower promotional spending.
  
• Roth Capital believes Watson Pharmaceuticals (NYSE: WPI) is about to enter a growth phase with Paul Bisaro at the helm and is positive on Silodosin potential. The firm upgraded shares to Buy from Hold.

OTHER UPGRADES:

• Bank of the Ozarks (NASDAQ: OZRK) was upgraded to Buy from Neutral at B. Riley.
  
• Bear upgraded Harman International (NYSE: HAR) to Outperform from Market Perform.
  
• Goldman upgraded Packagaing Corporation (NYSE: PKG) and Smurfit-Stone Container (NASDAQ: SSCC) to Buy from Neutral.
  
• Friedman Billings raised Conseco Inc (NYSE: CNO) to Outperform from Market Perform.

California-based Watson Pharmaceuticals, Inc. (NYSE: WPI) posted good 1Q 2007 numbers overall. For the quarter, net revenue was $671.6 million, with net income of $31.6 million and diluted EPS of $0.29. Factoring in some of the costs of acquiring Andrx Corporation, legal costs, and debt repurchase costs, adjusted net income was $37.3 million, $0.34 diluted EPS.

Watson Pharmaceuticals includes both generic and branded divisions, both of which reported double digit revenue increases. Generic division revenue was $424.6 million, up 32% or $102.5 million. This increase was driven by the sales of Andrx products as well as the sale of oxycodone HCI controlled-release tablets, the sale of which has been halted. Also sales of oral contraceptives products increased $9.6 million to $85.6 million. The much smaller branded division boosted net revenue for the quarter by 19% to $101.5 million, an increase of $16.4 million.

These positive numbers allowed the company to make $150 million worth of debt repayments in 1Q 2007. CEO Allen Chao states that the company is well placed to expand the number of generic and proprietary products it brings to market, while at the same time controlling operating costs and seeking out additional partners. Watson Pharmaceuticals is facing a number of additional costs related to its acquisition of Andrx Corporation, including over $23 million in additional administrative costs, and several million dollars worth of inventory charges for Andrx products. Pharmaceutical companies generally will face increased costs for clinical trials.

If the company is correct in its assessment of prescriptions trends, prescription prices, and the introduction of new products, then it forecasts FY 2007 net revenue between $2.5 and $2.6 billion.